Rhythm Pharmaceuticals Announces Publication of Bardet-Biedl Syndrome Patient and Caregiver Perspectives of Hunger and Quality of Life with Setmelanotide
27. März 2023 08:00 ET
|
Rhythm Pharmaceuticals, Inc.
- Interview-based research published in Advances in Therapy demonstrates setmelanotide improved hyperphagia and reduced body weight and obsessive focus on food – - Company also announces publication...
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
06. März 2023 16:01 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, March 06, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
01. März 2023 07:00 ET
|
Rhythm Pharmaceuticals, Inc.
-- IMCIVREE® U.S. launch for Bardet-Biedl syndrome (BBS) reflects strong demand with more than 200 new prescriptions received since FDA approval -- -- IMCIVREE now available in eight ex-U.S. markets;...
Rhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. and Portfolio of Investigational Therapeutics
27. Februar 2023 08:45 ET
|
Rhythm Pharmaceuticals, Inc.
- Rare disease company in preclinical development for congenital hyperinsulinism - - Acquisition is strong strategic fit with Rhythm’s rare endocrinology focus and provides meaningful new...
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Wednesday, March 1, 2023
21. Februar 2023 08:00 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
08. Februar 2023 08:00 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Announces Publication of Analysis of Quality of Life Improvements from Phase 3 Clinical Trial in Bardet-Biedl Syndrome
23. Januar 2023 08:00 ET
|
Rhythm Pharmaceuticals, Inc.
- Patients reported clinically meaningful improvements across multiple health-related quality of life measures following 52 weeks of treatment with setmelanotide - - Analysis published in Orphanet...
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
05. Januar 2023 16:01 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
07. Dezember 2022 16:01 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals to Present at BofA Securities 2022 Virtual Biotech SMID Cap Conference
01. Dezember 2022 08:00 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...